MedGenome launches genetic test to diagnose FSHD1

MedGenome launches genetic test to diagnose FSHD1

This new genetic test will help individuals with FSHD1 to get an early and accurate diagnosis, leading to improved disease management options.

FPJ News ServiceUpdated: Thursday, March 30, 2023, 04:46 PM IST
article-image
MedGenome launches genetic test to diagnose FSHD1 | Pixabay

For the first time, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) test has been launched by MedGenome Laboratory in India.

This new genetic test will help individuals with FSHD1 to get an early and accurate diagnosis, leading to improved disease management options.

The FSHD1 Optical Genome Mapping Test (OGM) is a highly advanced diagnostic tool that uses cutting-edge technology to provide a comprehensive and accurate assessment of genetic changes in patients with FSHD1.

Test can detect subtle changes in DNA

The test can detect large-scale insertions and duplications, as well as more subtle changes in DNA that can cause FSHD1[1].

Facioscapulohumeral Muscular Dystrophy (FSHD) is a common form of muscular dystrophy with an extremely complex genotype. It is progressive myopathy which accounts for 2 to 3% of muscular dystrophy cases in India.

FSHD1 is a rare genetic disorder that affects the muscles of the face, shoulder blades, and upper arms. The disease is caused by the deletion of genetic material from the D4Z4 repeat region on chromosome 4, leading to the loss of muscle tissue and weakness in affected areas.

FSHD1 affects approximately 1 in 20,000 individuals worldwide, with symptoms typically starting in early adulthood. FSHD1 can have a significant impact on quality of life, as it can result in difficulty with daily activities such as lifting objects or raising arms.

Disease can lead to severe disability

The disease is also progressive and can lead to severe disability in some cases. In the present day, there is no known cure for FSHD1, and treatment options are limited. However, many clinical trials are being conducted at an accelerated rate.

Vedam Ramprasad, PhD, CEO (India) of MedGenome Labs Ltd. said "We are thrilled to be the first in India to offer the Optical Genome Mapping Test for FSHD1. This is a significant step forward in our mission to provide the highest quality genetic testing services to clinicians and healthcare providers across the country. The launch of this new test represents a major milestone in the diagnosis and management of FSHD1 in India.”

Sakthivel Murugan SM, Vice President - Lab Operations, MedGenome Labs Ltd, said, "As a physician, I understand the challenges and concerns that patients with Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) face. This tool is a reliable and accurate diagnostic tool that will allow for early detection and personalized treatment plans. This test is a critical step forward in advancing precision medicine in India.”

RECENT STORIES

Mumbai: ED Raids Amber Dalal's Properties, Freezes ₹37 Crore In Assets

Mumbai: ED Raids Amber Dalal's Properties, Freezes ₹37 Crore In Assets

Mumbai News: 2 Firm Heads Booked For ₹6.6 Crore Fraud

Mumbai News: 2 Firm Heads Booked For ₹6.6 Crore Fraud

Rainy Season Woes: Ghatkopar's Railway Police Colony Plagued By Leaks And Crumbling Infrastructure

Rainy Season Woes: Ghatkopar's Railway Police Colony Plagued By Leaks And Crumbling Infrastructure

Mumbai: Advocate To Go On Indefinite Hunger Strike Against Rampant Corruption And Illegality In...

Mumbai: Advocate To Go On Indefinite Hunger Strike Against Rampant Corruption And Illegality In...

Mumbai: Doctors, IT Professionals Join Pilgrims' Route To Pandharpur

Mumbai: Doctors, IT Professionals Join  Pilgrims' Route To Pandharpur